Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Enlivex Therapeutics Ltd (ENLV)

Enlivex Therapeutics Ltd (ENLV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,758
  • Shares Outstanding, K 21,406
  • Annual Sales, $ 0 K
  • Annual Income, $ -29,070 K
  • EBIT $ -19 M
  • EBITDA $ -18 M
  • 60-Month Beta 1.01
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.98

Options Overview Details

View History
  • Implied Volatility 344.79% ( -3.45%)
  • Historical Volatility 98.88%
  • IV Percentile 83%
  • IV Rank 50.19%
  • IV High 674.98% on 11/15/24
  • IV Low 12.13% on 01/22/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 7
  • Volume Avg (30-Day) 104
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 2,282
  • Open Int (30-Day) 1,732

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.16
  • Number of Estimates 1
  • High Estimate -0.16
  • Low Estimate -0.16
  • Prior Year -0.48
  • Growth Rate Est. (year over year) +66.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8101 +54.30%
on 11/21/24
1.3465 -7.17%
on 12/04/24
-0.0200 (-1.57%)
since 11/06/24
3-Month
0.8101 +54.30%
on 11/21/24
1.7600 -28.98%
on 09/13/24
-0.0200 (-1.57%)
since 09/06/24
52-Week
0.8101 +54.30%
on 11/21/24
4.5900 -72.77%
on 04/03/24
-0.5300 (-29.78%)
since 12/06/23

Most Recent Stories

More News
Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3

NESS ZIONA, ISRAEL / ACCESSWIRE / November 26, 2024 / Enlivex Therapeutics Ltd. (Nasdaq:ENLV)(the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, is pleased to invite investors...

ENLV : 1.2500 (+2.46%)
Enlivex Therapeutics Ltd. Approves Purchase of Up to $1 Million in Bitcoin as Part of Cash Management Strategy

Enlivex Therapeutics plans to purchase $1 million in Bitcoin to diversify its treasury reserves amid increasing demand.Quiver AI SummaryEnlivex Therapeutics Ltd., a clinical-stage company focused on macrophage...

ENLV : 1.2500 (+2.46%)
New Strong Buy Stocks for October 23rd

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Rent the Runway, Inc. RENT: This designer clothing rental company has seen the Zacks Consensus Estimate for its current year earnings...

ENLV : 1.2500 (+2.46%)
PTON : 10.01 (+3.73%)
GTEC : 2.09 (+2.96%)
DSGR : 39.51 (+0.69%)
RENT : 12.82 (+13.96%)
CREA Stats, U.S. Retail Sales Featured Next Week

Monday U.S. Featured Earnings Lennar Corp. (NYSE: LEN) (Q2) EPS of $3.20, compared to $2.94 ...

FLOW.TO : 0.1450 (unch)
ET.TO : 12.42 (+0.32%)
ASTL.TO : 14.39 (+0.42%)
LEN : 163.45 (-0.93%)
LZB : 44.72 (-0.25%)
DDD : 2.90 (+7.41%)
KBH : 78.53 (+0.20%)
CRMT : 53.64 (+1.21%)
DLNG : 4.47 (-2.83%)
PDCO : 22.92 (+0.39%)
SCS : 13.37 (+1.98%)
KR : 59.23 (-2.44%)
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra™

Nes-Ziona, Israel, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming...

ENLV : 1.2500 (+2.46%)
Sheba Medical Center and Enlivex Announce Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers

First clinical trial of Allocetra™ in patients with cancer builds upon promising preclinical studies demonstrating its broadly applicable immunotherapeutic...

ENLV : 1.2500 (+2.46%)
Enlivex to Present at the 2022 Jefferies Healthcare Conference

Nes-Ziona, Israel, June 07, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy...

ENLV : 1.2500 (+2.46%)
Enlivex Announces Upcoming May Conference Presentations

Nes-Ziona, Israel, May 10, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming...

ENLV : 1.2500 (+2.46%)
Enlivex Presented Substantial Survival Benefit of Allocetra in Combination with Immune Checkpoint Inhibitor in Mesothelioma Cancer Study at the International Society for Cell and Gene Therapy Annual 2022 Meeting

Mesothelioma is one of the deadliest solid cancers, with few treatment options, all of which have limited efficacy. Immune checkpoint inhibitors targeting...

ENLV : 1.2500 (+2.46%)
Enlivex Announces Issuance of Two U.S. Patents Covering Methods of Treating Sepsis with Allocetra

Nes-Ziona, Israel, May 05, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming...

ENLV : 1.2500 (+2.46%)

Business Summary

Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome)...

See More

Key Turning Points

3rd Resistance Point 1.3767
2nd Resistance Point 1.3233
1st Resistance Point 1.2867
Last Price 1.2500
1st Support Level 1.1967
2nd Support Level 1.1433
3rd Support Level 1.1067

See More

52-Week High 4.5900
Fibonacci 61.8% 3.1461
Fibonacci 50% 2.7001
Fibonacci 38.2% 2.2540
Last Price 1.2500
52-Week Low 0.8101

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar